Literature DB >> 11803358

Relapse of Graves' disease after successful allogeneic bone marrow transplantation.

L T Hsiao1, J H Liu, C C Yen, W S Wang, F S Fan, T J Chiou, P M Chen.   

Abstract

As shown in many reports, allogeneic BMT can help cure autoimmune diseases. Conversely, we present a 24-year-old woman with Graves' disease, which was diagnosed just before BMT for CML. The Graves' disease remitted immediately after BMT but relapsed 18 months later. Since the donor was free from thyroid diseases and the patient showed a rapid shift to complete donor chimerism after BMT, the autoimmune problem seemed neither to arise directly from the donor nor simply from the recipient's residual lymphocytes. On the contrary, it was most likely compounded by chronic GVHD as suggested by the accompanying GVHD symptoms and the absolute donor karyotype in bone marrow cells. A Graves' disease-susceptible HLA allele was also shared between recipient and donor, possibly enhancing the chances of this condition developing. Thus, allogeneic BMT may facilitate relapses in autoimmune diseases as well as alleviating them.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11803358     DOI: 10.1038/sj.bmt.1703291

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

Review 2.  2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.

Authors:  Ilaria Muller; Carla Moran; Beatriz Lecumberri; Brigitte Decallonne; Neil Robertson; Joanne Jones; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2019-07-04

Review 3.  Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.

Authors:  Aryan Rafiee Zadeh; Keyvan Ghadimi; Akram Ataei; Mozhde Askari; Neda Sheikhinia; Nooshin Tavoosi; Masih Falahatian
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-08-15

Review 4.  Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.

Authors:  Yi-chi M Kong; Wei-Zen Wei; Yaron Tomer
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

Review 5.  [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].

Authors:  C Warnke; B C Kieseier; U Zettl; H-P Hartung
Journal:  Nervenarzt       Date:  2009-04       Impact factor: 1.214

6.  Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects.

Authors:  Onajite Kousin-Ezewu; Alasdair Coles
Journal:  Ther Adv Chronic Dis       Date:  2013-05       Impact factor: 5.091

Review 7.  Alemtuzumab therapy for multiple sclerosis.

Authors:  Alasdair J Coles
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.